S
Steven Zacks
Researcher at University of North Carolina at Chapel Hill
Publications - 39
Citations - 2996
Steven Zacks is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 23, co-authored 39 publications receiving 2730 citations.
Papers
More filters
Journal ArticleDOI
Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study
Naga Chalasani,Herbert L. Bonkovsky,Robert J. Fontana,William M. Lee,Andrew Stolz,Jayant A. Talwalkar,K. Rajendar Reddy,Paul B. Watkins,Victor J. Navarro,Huiman X. Barnhart,Jiezhun Gu,Jose Serrano,Jawad Ahmad,Nancy Bach,Meena B. Bansal,Huiman X. Barnhart,Kimberly L. Beavers,Herbert L. Bonkovsky,Francisco O. Calvo,Charissa Y. Chang,Hari S. Conjeevaram,Gregory E. Conner,Jama M. Darling,Ynto S. de Boer,Douglas T. Dieterich,Frank DiPaola,Francisco A. Durazo,James E. Everhart,Robert J. Fontana,Marwan Ghabril,David Goldstein,Vani Gopalreddy,Priya Grewal,Paul H. Hayashi,Jay H. Hoofnagle,Neil Kaplowitz,Suthat Liangpunsakul,Steven N. Lichtman,Lawrence Liu,Victor Navarro,Joseph A. Odin,Simona Rossi,Mark W. Russo,Thomas D. Schiano,Averell H. Sherker,Raj Vuppalanchi,Paul B. Watkins,Steven Zacks,Amanda Balasco,Kristin Chesney,Audrey Corne,Sherrie Cummings,Gale Groseclose,Alex Hammett,Judy Hooker,Varun Kesar,Sophana Mao,Kenari Marks,Regina McFadden,Yolanda Melgoza,Sherif Mikhail,Susan Milstein,Wendy Morlan,Val Peacock,Nidia Rosado,Tracy Russell,Maricruz Vega,Manisha Verma,Patricia F. Walker,Rachana Yalamanchili,Michelle McClanahan-Crowder,Katherine Galan,Tuan Chau,Kowsalya Ragavan,Hoss Rostami,Carmel Puglisi-Scharenbroich,Rebecca Torrance,Rebekah Van Raaphorst +77 more
TL;DR: In this article, the authors present characteristics and subgroup analyses from the first 1257 patients enrolled in the study, and conclude that there are no differences in outcomes of patients with short vs long latency of DILI.
Journal ArticleDOI
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response†
Jordan J. Feld,Santosh Nanda,Ying Huang,Weiping Chen,Maggie Cam,Susan N. Pusek,Lisa M. Schweigler,Dickens Theodore,Steven Zacks,T. Jake Liang,Michael W. Fried +10 more
TL;DR: The data suggest that ISG inducibility is important for the treatment response and that ribavirin may improve outcomes by enhancing hepatic gene responses to peginterferon, and these mechanisms may provide a molecular basis for the improved efficacy of combination therapy.
Journal ArticleDOI
Impact of Hepatopulmonary Syndrome on Quality of Life and Survival in Liver Transplant Candidates
Michael B. Fallon,Michael J. Krowka,Robert S. Brown,James F. Trotter,Steven Zacks,Kari E. Roberts,Vijay H. Shah,Neil Kaplowitz,Lisa Forman,Keith M. Wille,Steven M. Kawut +10 more
TL;DR: HPS was associated with a significant increase in risk of death as well as worse functional status and quality of life in patients evaluated for liver transplantation.
Journal ArticleDOI
Clinical Risk Factors for Portopulmonary Hypertension
Steven M. Kawut,Michael J. Krowka,James F. Trotter,Kari E. Roberts,Raymond L. Benza,David B. Badesch,Darren B. Taichman,Evelyn M. Horn,Steven Zacks,Neil Kaplowitz,Robert S. Brown,Michael B. Fallon +11 more
TL;DR: Female sex and autoimmune hepatitis were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infection was associated with a decreased risk in patients with advanced liver disease, suggesting Hormonal and immunologic factors may be integral to the development ofportopul pulmonary hypertension.
Journal ArticleDOI
Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease
Kari E. Roberts,Michael B. Fallon,Michael J. Krowka,Robert S. Brown,James F. Trotter,Inga Peter,Hocine Tighiouart,James A. Knowles,Daniel Rabinowitz,Raymond L. Benza,David B. Badesch,Darren B. Taichman,Evelyn M. Horn,Steven Zacks,Neil Kaplowitz,Steven M. Kawut +15 more
TL;DR: Genetic variation in estrogen signaling and cell growth regulators is associated with the risk of portal hypertension in patients with advanced liver disease and these biologic pathways may elucidate the mechanism for the development of PPHTN in certain patients with severe liver disease.